Eli Lilly and Company (NYSE:LLY) Shares Sold by Bridgeway Capital Management LLC

Bridgeway Capital Management LLC trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 7.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,604 shares of the company's stock after selling 2,483 shares during the period. Eli Lilly and Company comprises approximately 0.5% of Bridgeway Capital Management LLC's holdings, making the stock its 16th biggest holding. Bridgeway Capital Management LLC's holdings in Eli Lilly and Company were worth $23,626,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Principal Financial Group Inc. raised its position in shares of Eli Lilly and Company by 5.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock valued at $1,070,698,000 after purchasing an additional 60,306 shares in the last quarter. Nordea Investment Management AB raised its stake in Eli Lilly and Company by 13.7% during the 4th quarter. Nordea Investment Management AB now owns 1,154,350 shares of the company's stock valued at $887,014,000 after acquiring an additional 138,835 shares in the last quarter. Legacy Wealth Management LLC MS bought a new position in Eli Lilly and Company in the 4th quarter valued at about $215,000. CWA Asset Management Group LLC lifted its stake in shares of Eli Lilly and Company by 11.9% in the 4th quarter. CWA Asset Management Group LLC now owns 6,794 shares of the company's stock worth $5,245,000 after acquiring an additional 724 shares during the period. Finally, Neville Rodie & Shaw Inc. lifted its holdings in shares of Eli Lilly and Company by 0.6% in the fourth quarter. Neville Rodie & Shaw Inc. now owns 15,031 shares of the company's stock valued at $11,604,000 after buying an additional 97 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Guggenheim restated a "buy" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their price objective for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. StockNews.com upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. Finally, The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their target price for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,002.80.

Eli Lilly and Company Stock Up 0.2 %

Shares of NYSE LLY traded up $1.82 on Wednesday, reaching $776.94. 3,805,023 shares of the company's stock traded hands, compared to its average volume of 3,489,329. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The business's 50 day simple moving average is $818.04 and its two-hundred day simple moving average is $813.77. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The company has a market cap of $736.33 billion, a price-to-earnings ratio of 66.35, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter last year, the company earned $2.58 EPS. The firm's revenue for the quarter was up 45.2% on a year-over-year basis. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.77%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.14% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.